Brief: Knight Therapeutics Announces Approval Of Ibsrela™ In Canada
17/04/2020 12:33
April 17 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS ANNOUNCES APPROVAL OF IBSRELA™ IN
CANADA
* KNIGHT THERAPEUTICS - HEALTH CANADA APPROVED IBSRELA FOR
TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN
ADULTS
Source text for Eikon: ID:nGNX3mvrFD
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil